Progress in treating inherited retinal diseases : Early subretinal gene therapy clinical trials and candidates for future initiatives
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Due to improved phenotyping and genetic characterization, the field of 'incurable' and 'blinding' inherited retinal diseases (IRDs) has moved substantially forward. Decades of ascertainment of IRD patient data from Philadelphia and Toronto centers illustrate the progress from Mendelian genetic types to molecular diagnoses. Molecular genetics have been used not only to clarify diagnoses and to direct counseling but also to enable the first clinical trials of gene-based treatment in these diseases. An overview of the recent reports of gene augmentation clinical trials by subretinal injections is used to reflect on the reasons why there has been limited success in this early venture into therapy. These first-in human experiences have taught that there is a need for advancing the techniques of delivery of the gene products - not only for refining further subretinal trials, but also for evaluating intravitreal delivery. Candidate IRDs for intravitreal gene delivery are then suggested to illustrate some of the disorders that may be amenable to improvement of remaining central vision with the least photoreceptor trauma. A more detailed understanding of the human IRDs to be considered for therapy and the calculated potential for efficacy should be among the routine prerequisites for initiating a clinical trial.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
---|---|
Enthalten in: |
Progress in retinal and eye research - 77(2020) vom: 30. Juli, Seite 100827 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Garafalo, Alexandra V [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 11.12.2020 Date Revised 03.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.preteyeres.2019.100827 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM304988812 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM304988812 | ||
003 | DE-627 | ||
005 | 20231225120158.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.preteyeres.2019.100827 |2 doi | |
028 | 5 | 2 | |a pubmed24n1016.xml |
035 | |a (DE-627)NLM304988812 | ||
035 | |a (NLM)31899291 | ||
035 | |a (PII)S1350-9462(19)30114-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Garafalo, Alexandra V |e verfasserin |4 aut | |
245 | 1 | 0 | |a Progress in treating inherited retinal diseases |b Early subretinal gene therapy clinical trials and candidates for future initiatives |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.12.2020 | ||
500 | |a Date Revised 03.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
520 | |a Due to improved phenotyping and genetic characterization, the field of 'incurable' and 'blinding' inherited retinal diseases (IRDs) has moved substantially forward. Decades of ascertainment of IRD patient data from Philadelphia and Toronto centers illustrate the progress from Mendelian genetic types to molecular diagnoses. Molecular genetics have been used not only to clarify diagnoses and to direct counseling but also to enable the first clinical trials of gene-based treatment in these diseases. An overview of the recent reports of gene augmentation clinical trials by subretinal injections is used to reflect on the reasons why there has been limited success in this early venture into therapy. These first-in human experiences have taught that there is a need for advancing the techniques of delivery of the gene products - not only for refining further subretinal trials, but also for evaluating intravitreal delivery. Candidate IRDs for intravitreal gene delivery are then suggested to illustrate some of the disorders that may be amenable to improvement of remaining central vision with the least photoreceptor trauma. A more detailed understanding of the human IRDs to be considered for therapy and the calculated potential for efficacy should be among the routine prerequisites for initiating a clinical trial | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Review | |
650 | 4 | |a ABCA4 | |
650 | 4 | |a BCM | |
650 | 4 | |a CNGA3 | |
650 | 4 | |a CNGB3 | |
650 | 4 | |a Gene therapy | |
650 | 4 | |a Genetic retinal degenerations | |
650 | 4 | |a Leber congenital amaurosis | |
650 | 4 | |a MERTK | |
650 | 4 | |a MYO7A | |
650 | 4 | |a Molecular mechanisms | |
650 | 4 | |a NPHP5 | |
650 | 4 | |a OPN1LW | |
650 | 4 | |a OPN1MW | |
650 | 4 | |a PDE6B | |
650 | 4 | |a REP1 | |
650 | 4 | |a RLBP1 | |
650 | 4 | |a RPE65 | |
650 | 4 | |a RPGR | |
650 | 4 | |a RPGRIP1 | |
650 | 4 | |a Retinitis pigmentosa | |
650 | 4 | |a TULP1 | |
700 | 1 | |a Cideciyan, Artur V |e verfasserin |4 aut | |
700 | 1 | |a Héon, Elise |e verfasserin |4 aut | |
700 | 1 | |a Sheplock, Rebecca |e verfasserin |4 aut | |
700 | 1 | |a Pearson, Alexander |e verfasserin |4 aut | |
700 | 1 | |a WeiYang Yu, Caberry |e verfasserin |4 aut | |
700 | 1 | |a Sumaroka, Alexander |e verfasserin |4 aut | |
700 | 1 | |a Aguirre, Gustavo D |e verfasserin |4 aut | |
700 | 1 | |a Jacobson, Samuel G |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Progress in retinal and eye research |d 1997 |g 77(2020) vom: 30. Juli, Seite 100827 |w (DE-627)NLM093752423 |x 1873-1635 |7 nnns |
773 | 1 | 8 | |g volume:77 |g year:2020 |g day:30 |g month:07 |g pages:100827 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.preteyeres.2019.100827 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 77 |j 2020 |b 30 |c 07 |h 100827 |